Orchestra BioMed Has A Clearer Trial Timeline But A Demanding Valuation
Summary Orchestra BioMed is rated Hold at $5.72 pending pivotal trial data for its hypertension therapy delivered via pacemaker, with results expected in Q2 2027. AVIM Therapy and Virtue Sirolimus AngioInfusion Balloon represent distinct commercial …